Download PDF

Register to download the report. Already a member?

Sign Up


71729 1526457625HCLS_ECUADOR_Final.pdf
Energy Boardroom

Type your email in the box below to read this content NOW:


Svatopluk Betina – Country Manager, Lundbeck Slovakia

svatopluk-betina-country-manager-lundbeck-slovakiaLundbeck Slovakia Country Manager, Svatopluk Betina, reflects on the performance of one of the most innovative pharmaceutical firms in the region and the challenges companies face when introducing new products to the market

Can you please provide an overview of Lundbeck’s presence in Slovakia and share with our audience the performance of the company in 2016?

Lundbeck has been operating in Slovakia for 22 years (established in 1994) and is still focused solely on the research and development of Central Nervous System (CNS) pharmaceuticals. Calculating the number of patients that have been treated with our drugs and their relatives we have positively influenced the quality of life of approximately one million people. We are really proud of our impact and we will continue to focus on our specialty – CNS. Right now, we are experiencing a transitionary phase because last year we introduced two new drugs to the market. An anti-depressant, Brintellix and an anti-psychotic injection called Abilify Maintena. In one year, we have managed to get two new drugs into the market which as an objective is far from easy. It is a great achievement but it is also a lot of work behind it.



Most Read

Download PDF

First Name:

Last Name: